A diagnostics technology platform for immuno-oncology

HealthTech
Other

About Asylia Diagnostics

We empower cancer patients, medical oncologists, and drug development companies to have an informed decision about the safety of immunotherapy by providing reliable companion diagnostics technology platform. Our first product - already in clinical studies in Belgium - is targeting hyperprogressive disease, a severe adverse effect of immune checkpoint blockade affecting 5-29% of patients.

Our involvement

Asylia Diagnostics joined imec.istart in 2019

Asylia Diagnostics logo

‘Belgium is a frontrunner in biotech and healthtech, imec.istart is our connection to that ecosystem’

Read the story